See the DrugPatentWatch profile for Esperoct
What is Esperoct?
Esperoct is a recombinant coagulation factor VIII (rFVIII) therapy used to treat hemophilia A. It is a modified form of the naturally occurring factor VIII protein, designed to have a longer half-life, meaning it stays in the body longer than previous treatments [1]. This allows for less frequent dosing, typically once a week, compared to older factor VIII concentrates which often required administration several times a week [1][2]. Esperoct is administered intravenously.
How does Esperoct work for hemophilia A?
Hemophilia A is a genetic bleeding disorder caused by a deficiency in functional factor VIII, a crucial protein in the blood clotting cascade. Esperoct, as a recombinant factor VIII, provides a functional version of this missing protein. When infused, it circulates in the bloodstream and, in the event of an injury, helps to initiate the clotting process, thereby preventing or stopping prolonged bleeding [1]. Its extended half-life is achieved through modifications that reduce its clearance from the body, offering sustained levels of factor VIII activity [1].
When does Esperoct's patent expire?
The patent exclusivity for Esperoct is a complex landscape involving multiple patents covering different aspects of the drug, including its formulation and use. According to DrugPatentWatch.com, patent expiry dates can vary for different patents associated with a drug. For Esperoct, the earliest key patents protecting its core technology began to expire around 2032 [3]. However, the full picture of patent expiry and potential generic or biosimilar entry is subject to ongoing legal challenges and the specific patents that remain active and in force [3].
Who makes Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What clinical data supports Esperoct's efficacy?
Clinical trials have demonstrated Esperoct's effectiveness in reducing annualized bleeding rates (ABR) in adults and children with hemophilia A. Studies showed a significant reduction in treated bleeds per year for patients on weekly prophylaxis with Esperoct compared to their previous treatment regimens [1][2]. The therapy has also been shown to be effective in managing bleeding episodes and in perioperative settings [1].
What are the risks and side effects associated with Esperoct?
Like other factor VIII therapies, the primary risks associated with Esperoct include allergic reactions and the development of neutralizing antibodies (inhibitors) against factor VIII, which can reduce the treatment's effectiveness [1]. Common side effects reported in clinical trials include headache, cough, fever, and reactions at the injection site [1].
Can biosimilars of Esperoct be developed?
The development of biosimilars for biologic drugs like Esperoct is possible once patent exclusivity and regulatory exclusivities expire. Biosimilars are highly similar to the reference biologic drug, with no clinically meaningful differences in safety, purity, and potency. The pathway to biosimilar approval involves demonstrating this high degree of similarity through extensive analytical, preclinical, and clinical studies. The timeline for biosimilar entry for Esperoct will be influenced by the remaining patent protections and any regulatory exclusivities [3].